Suzhou-based Accro Bioscience closed a $50 million Series C financing led by OrbiMed, funding continued development of its oral immune-mediated disease pipeline. The round also included participation from TCG Crossover, LAV, Cenova Capital and other investors. Accro described its strategy as centered on delivering orally administered therapies for patients with immune-mediated conditions, with the financing aimed at advancing platform execution and clinical progress. The company’s statement emphasized investor backing as a continuation of its development plan. For the biotech market, the round highlights ongoing institutional appetite for oral modalities in immunology—particularly strategies that can differentiate on dosing convenience while maintaining competitive efficacy and manufacturability.